FHIRsmith: ValueSet/ValueSet-R4-v3-substanceAdminSubstitution-for-R4B.json

FHIR IG analytics

Package	hl7.fhir.uv.xver-r4.r4b.r4b
Resource Type	ValueSet
Id	ValueSet-R4-v3-substanceAdminSubstitution-for-R4B.json
FHIR Version	R4B

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: ValueSet R4-v3-substanceAdminSubstitution-for-R4B

This value set expansion contains 9 concepts.

Code	System	Display	Definition
BC	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	brand composition	Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
G	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	generic composition	Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
EC	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	equivalent composition	Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
TB	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	therapeutic brand	Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics Examples: Zantac for Tagamet
TG	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	therapeutic generic	Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands Examples: Ranitidine for cimetidine
TE	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	therapeutic alternative	Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
E	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	equivalent	Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
F	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	formulary	This substitution was performed or is permitted based on formulary guidelines.
N	http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution	none	No substitution occurred or is permitted.

Source1

{
  "resourceType": "ValueSet",
  "id": "R4-v3-substanceAdminSubstitution-for-R4B",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
      "valueInteger": 0
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
      "valueCode": "vocab"
    },
    {
      "extension": [
        {
          "url": "packageId",
          "valueId": "hl7.fhir.uv.xver-r4.r4b"
        },
        {
          "url": "version",
          "valueString": "0.0.1-snapshot-2"
        }
      ],
      "url": "http://hl7.org/fhir/StructureDefinition/package-source"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
      "valueCode": "trial-use",
      "_valueCode": {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
            "valueCanonical": "http://hl7.org/fhir/4.0/ImplementationGuide/hl7.fhir.uv.xver-r4.r4b"
          }
        ]
      }
    }
  ],
  "url": "http://hl7.org/fhir/4.0/ValueSet/R4-v3-substanceAdminSubstitution-for-R4B",
  "version": "0.0.1-snapshot-2",
  "name": "R4_v3_substanceAdminSubstitution_for_R4B",
  "title": "Cross-version VS for R4.v3.substanceAdminSubstitution for use in FHIR R4B",
  "status": "active",
  "experimental": false,
  "date": "2025-09-01T22:36:21.982925+10:00",
  "publisher": "HL7 International / Terminology Infrastructure",
  "contact": [
    {
      "name": "HL7 International / Terminology Infrastructure",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/Vocab"
        }
      ]
    }
  ],
  "description": "This cross-version ValueSet represents concepts from http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution|2018-08-12 for use in FHIR R4B. Concepts not present here have direct `equivalent` mappings crossing all versions from R4 to R4B.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "001",
          "display": "World"
        }
      ]
    }
  ],
  "compose": {
    "include": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "concept": [
          {
            "code": "BC",
            "display": "brand composition"
          },
          {
            "code": "G",
            "display": "generic composition"
          },
          {
            "code": "EC",
            "display": "equivalent composition"
          },
          {
            "code": "TB",
            "display": "therapeutic brand"
          },
          {
            "code": "TG",
            "display": "therapeutic generic"
          },
          {
            "code": "TE",
            "display": "therapeutic alternative"
          },
          {
            "code": "E",
            "display": "equivalent"
          },
          {
            "code": "F",
            "display": "formulary"
          },
          {
            "code": "N",
            "display": "none"
          }
        ]
      }
    ]
  },
  "expansion": {
    "timestamp": "2025-09-01T22:36:21.982928+10:00",
    "contains": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "BC",
        "display": "brand composition"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "G",
        "display": "generic composition"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "EC",
        "display": "equivalent composition"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "TB",
        "display": "therapeutic brand"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "TG",
        "display": "therapeutic generic"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "TE",
        "display": "therapeutic alternative"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "E",
        "display": "equivalent"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "F",
        "display": "formulary"
      },
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution",
        "version": "2018-08-12",
        "code": "N",
        "display": "none"
      }
    ]
  }
}